ARTICLE | Company News
University Health Network, Avrobio deal
February 22, 2016 8:00 AM UTC
Avrobio gained exclusive, worldwide rights to two cell therapy candidates from University Health Network (UHN) to treat acute myelogenous leukemia (AML) and Fabry’s disease. By mid-2016, the newco said it expects to begin Phase I trials of both candidates, with data expected this year. ...